Daily, Fri 6 Nov: Bayer Sunharbo China FXIa OK; Qyuns–Caldera, Hinova–Evommune; InnoCare ITP

Full transcript, with sources

Numbers in [brackets] link to the sources at the end of the section or episode. Chinese names are given in characters with Hanyu Pinyin; on air, Ning says them in Mandarin.

[opening music]

Opening

BasilChina gives Bayer the world's first Factor Eleven-A stroke pill. Two Chinese biotechs license autoimmune drugs out for thirty million dollars each upfront. And a Hong Kong eye-drug maker says its Phase Three hit both goals, while its shares stay suspended.

BasilI'm Basil Lui, and I invest globally from Singapore, backing growth-stage companies with an Asia angle. This is The East-West Bio Brief, biotech and beyond, and it's the daily edition for Friday, November sixth.

NingAnd I'm Ning. As always, these are our own voices, AI-cloned so we can bring you this every morning. Personal views, not investment advice.

China

BasilLet's start in China, with a stroke drug that our October thirty-first pilot only flagged in passing.

NingChina's drug regulator approved Bayer's asundexian on October twenty-sixth, sold as Sunharbo, in Chinese, 舒华博 (Shū Huá Bó), also known by the generic name 阿舒克森 (Ā Shū Kè Sēn). It's a once-daily pill, and Bayer says it's the world's first Factor Eleven-A inhibitor. Factor Eleven is a clotting protein. Blocking the activated form aims to cut the risk of another stroke after a non-heart-related ischaemic stroke or a high-risk mini-stroke, without the big bleed rise older blood thinners can bring.

NingIn the twelve-thousand-three-hundred-and-twenty-seven-patient OCEANIC-STROKE trial, published in the New England Journal of Medicine, repeat ischaemic stroke fell to six point two percent from eight point four percent on antiplatelet therapy alone, a twenty-six percent relative cut, with no significant rise in major bleeding. China got the first approval. Applications elsewhere are under review, and the US Food and Drug Administration decision is due around November ninth.

BasilSo China is first with an approved Factor Eleven-A pill, and the next read is whether the United States follows around November ninth. Next, deals, and the China-out licensing beat we ran on Thursday with Boehringer and Minghui continues.

NingQyuns Therapeutics, in Chinese, 荃信生物 (Quán Xìn Shēngwù), licensed worldwide rights to a preclinical antibody that blocks two inflammation signals, T-L-one-A and I-L-seventeen, to Caldera Therapeutics. Qyuns gets thirty million US dollars upfront and up to seven hundred and fifty million in milestones. The antibody is aimed at immune diseases and is not yet in human trials.

NingAnd Chengdu's [成都, Chéngdū] Hinova, in Chinese, 海创药业 (Hǎi Chuàng Yàoyè), licensed rights outside Greater China to H-P-five-seventy, also called E-V-O-five-seventy, to Evommune. It's an oral molecular glue that makes cells break down V-A-V-one, a protein that switches on immune cells, aimed at autoimmune disease. Hinova gets thirty million US dollars upfront, twenty million in cash plus ten million in warrants, and up to about one point oh seven billion in milestones. A US Phase One is about to start.

BasilSo two China-out autoimmune deals on the same news cycle, each with thirty million upfront, which is the cash that counts before the milestone headlines.

NingAnd that sits against Endpoints' Q-three survey of five hundred and sixty-nine biopharma insiders. Innovation in China is now the number-two worry, at fourteen percent of respondents, up from sixth place. Yet eleven percent still name it their top reason for optimism. Big Pharma keeps licensing from China, and Endpoints says the industry is on pace for about one China deal a week this year. That tension, worry on one side and shopping on the other, is the East-West beat we keep coming back to.

BasilNext, the clinic, and a company press release.

NingInnoCare, in Chinese, 诺诚健华 (Nuò Chéng Jiànhuá), says its Phase Three of orelabrutinib, in Chinese, 奥布替尼 (Ào Bù Tìní), met its main goal in chronic I-T-P. That's an autoimmune disease where the body destroys its own platelets and causes bruising and bleeding. Orelabrutinib is a daily pill that blocks B-T-K, an enzyme immune B-cells use.

NingIn one hundred and ninety-six Chinese adults, thirty-two point eight percent kept a durable platelet response, twenty-five point five points better than placebo, and median time to response was fourteen days versus forty-two. It gets an oral slot at the American Society of Hematology meeting on December fourteenth, and a China marketing application is already accepted. This is a company press release, with Chinese patients only.

BasilOne more clinic read, also a company press release, from a Hong Kong-listed eye company whose shares are suspended.

NingCloudbreak Pharma, in Chinese, 拨康视云 (Bō Kāng Shìyún), says its eye drop C-B-T-zero-zero-one met both main goals in a six-hundred-and-fifty-nine-patient Phase Three for pterygium, a fleshy U-V-linked growth that creeps over the eye's surface. The drop is a multi-kinase inhibitor reformulated from nintedanib that curbs new blood vessels and scarring. It reduced redness at three months and slowed lesion growth at twelve months, about ten percent of baseline versus placebo. Surface irritation was twenty percent versus eight percent on placebo. Cloudbreak shares have been suspended since September tenth at the Securities and Futures Commission's direction. Grand Pharma, in Chinese, 远大医药 (Yuǎn Dà Yīyào), holds the Greater China rights. The company says F-D-A talks come next, and this is a company press release.

Wider Asia

BasilLet's head beyond China, starting in Korea.

NingProteina, listed on KOSDAQ, is raising about thirty-six point five billion won, including twenty-six billion to build an A-I-run biofoundry, an automated wet lab, for protein-interaction drug discovery. Its shares rose about thirteen percent on the news. The health angle is faster, automated lab data for designing drugs that work through how proteins talk to each other.

Rest of the world

BasilNow, the rest of the world, and a rare-disease buyout in Europe.

NingA-N-I Pharmaceuticals made a recommended offer of about five hundred and sixty million US dollars for Sweden's Egetis. Egetis sells Emcitate, also called tiratricol, the first approved drug for M-C-T-eight deficiency, a rare inherited disorder that blocks thyroid hormone from reaching the brain.

Beyond Biotech

NingNow, beyond biotech. Tianjin University's [天津, Tiānjīn] brain-machine lab filed the first non-invasive brain-computer-interface clinical study under China's new medical-technology rules. The device combines a brain-signal cap, spinal cord stimulation and a powered leg exoskeleton for chronic post-stroke leg weakness. In an earlier pilot, one sixty-seven-year-old walked unaided after twenty-two days, but that is a single patient.

BasilSo the health angle is retraining walking with the patient's own intent, and no surgery. That carries on the brain-tech thread from our November fourth and fifth episodes.

NingAnd on the device side, Chinese press reports that rising chip and component costs are squeezing makers. Imported C-T tubes are up twenty to thirty percent. Mindray, in Chinese, 迈瑞医疗 (Mài Ruì Yīliáo), expects a lower gross margin this year, and United Imaging, in Chinese, 联影医疗 (Lián Yǐng Yīliáo), warns of lagged cost effects next year. Volume-based procurement caps what hospitals pay, so those costs are harder to pass on.

The mood

NingAnd the mood. On Thursday, November fifth, the Hang Seng Index [恒生指数, Héngshēng Zhǐshù] rose about three point seven percent to about twenty-four thousand eight hundred, its fifth straight gain, and the Hang Seng Healthcare index added about three point seven percent. In the US, the X-B-I biotech fund fell about six point six percent.

One thing to watch, call to action and sign-off

BasilMy one thing to watch is the US Food and Drug Administration's decision on asundexian, due around November ninth, which would show whether China's first-in-class Factor Eleven-A approval is followed in the United States. If it lands before Monday, we'll pick it up in the weekly.

BasilIf this brief helps your morning, follow The East-West Bio Brief on Spotify or Apple Podcasts.

NingAnd for our weekly roundup, subscribe to the LinkedIn newsletter, also called The East-West Bio Brief, which goes out every Monday.

NingThat's today's brief. The key sources are in the show notes. See you tomorrow.

[closing music]

Sources

1. Bayer media release, 26 Oct 2026: China's NMPA grants marketing authorization for asundexian under brand Sunharbo®, 50 mg once-daily oral Factor XIa inhibitor, to reduce stroke risk after non-cardioembolic ischemic stroke or high-risk TIA; first FXIa inhibitor approved worldwide; Priority Review; based on OCEANIC-STROKE; applications in other markets under review: https://www.bayer.com/media/en-us/asundexian-first-factor-xia-inhibitor-approved-in-china-for-stroke-risk-reduction-after-priority-review/

2. Bayer China, 26 Oct 2026: Chinese brand 舒华博（阿舒克森片）; NMPA approval; first-in-class FXIa; ischaemic stroke risk cut 26% vs placebo on antiplatelet background; no increase in ISTH major bleeding: https://www.bayer.com.cn/zh-cn/media/news/2026/shuhuabozhongguohuopi

3. China Food and Drug News (中国食品药品网 / CNPharm), 28 Oct 2026: NMPA approved 阿舒克森片 (Bayer AG) via priority review for reducing stroke risk after ischaemic stroke or high-risk TIA, excluding cardioembolic stroke: https://www.cnpharm.com/c/2026-10-28/1109526.shtml

4. NEJM OCEANIC-STROKE (doi 10.1056/NEJMoa2513880): Phase 3, 12,327 randomised; asundexian 50 mg + antiplatelet vs placebo + antiplatelet; ischaemic stroke 6.2% vs 8.4% (26% relative reduction); ISTH major bleeding similar: https://www.nejm.org/doi/10.1056/NEJMoa2513880

5. Neurology Advisor, Nov 2026 PDUFA calendar: FDA decision on asundexian expected around November 2026: https://www.neurologyadvisor.com/news/fda-drug-approval-decisions-expected-in-november-2026/

6. Pilot 31 Oct 2026 (callback): asundexian flagged in passing: https://eastwestbiobrief.com/episodes/2026-10-31-pilot-asia-biotech-decoded-for-investors/

7. Thu 5 Nov daily (callback): Hemay postponed; Boehringer–Sino / Minghui China-out beat: https://eastwestbiobrief.com/episodes/2026-11-05-daily-hemay-postponed-sino-biopharm-boehringer-nxera/

8. Qyuns Therapeutics / Caldera Therapeutics deal coverage (HKEX / company, 5–6 Nov 2026) — TL1A/IL-17 antibody; US$30M upfront

9. Hinova / Evommune deal coverage (company / Fierce, 5–6 Nov 2026) — HP570/EVO570 VAV1 molecular glue; US$30M upfront

10. Endpoints Q3 2026 biopharma survey: China innovation worry vs optimism; ~one China deal a week pace

11. InnoCare company press release, 5 Nov 2026: orelabrutinib Phase 3 chronic ITP; ASH oral 14 Dec; China NDA accepted

12. Cloudbreak Pharma company press release: CBT-001 pterygium Phase 3; shares suspended since 10 Sep at SFC direction; Grand Pharma Greater China rights

13. Proteina (KOSDAQ) AI biofoundry raise coverage, ~KRW 36.5B

14. ANI Pharmaceuticals recommended offer for Egetis (~US$560M); Emcitate/tiratricol for MCT8 deficiency

15. Tianjin University non-invasive BCI clinical study filing under China medical-technology rules

16. Chinese press on device-maker cost pressure: Mindray, United Imaging; CT tube costs; VBP

17. Market mood 5 Nov 2026: Hang Seng / Hang Seng Healthcare ~+3.7%; XBI ~−6.6%

18. Pinyin tones: pypinyin/CC-CEDICT; Bayer China / CNPharm for 舒华博 / 阿舒克森; HKEX for 荃信生物 and 拨康视云; company/SSE for 海创药业 and 诺诚健华